PURPOSE: The purpose of this study was to evaluate the role of magnetic resonance spectroscopic imaging (MRSI) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in detecting tumour foci in patients with elevated prostate-specific antigen (PSA) and negative transrectal ultrasonography (TRUS)-guided biopsy. MATERIALS AND METHODS: This prospective randomised trial was conducted on 150 patients who underwent [¹H]MRSI and DCE-MRI and targeted biopsies of suspicious areas on MRI associated with random biopsies. RESULTS: After the second biopsy, the diagnosis of prostate adenocarcinoma was made in 64/150 cases. On a per-patient basis, MRSI had 82.8% sensitivity, 91.8% specificity, 88.3% positive predictive value (PPV), 87.8% negative predictive value (NPV) and 85.7% diagnostic accuracy. The sensitivity, specificity, PPV, NPV and accuracy for DCE-MRI was 76.5%, 89.5%, 84.5%, 83.7% and 82%, respectively. The combination of MRSI and DCE-MRI yielded 93.7% sensitivity, 90.7% specificity, 88.2% PPV, 95.1% NPV and 90.9% accuracy in detecting prostate carcinoma. CONCLUSIONS: The combined study with [¹H]MRSI and DCE-MRI showed promising results in guiding the biopsy of cancer foci in patients with an initial negative TRUS-guided biopsy.
RCT Entities:
PURPOSE: The purpose of this study was to evaluate the role of magnetic resonance spectroscopic imaging (MRSI) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in detecting tumour foci in patients with elevated prostate-specific antigen (PSA) and negative transrectal ultrasonography (TRUS)-guided biopsy. MATERIALS AND METHODS: This prospective randomised trial was conducted on 150 patients who underwent [¹H]MRSI and DCE-MRI and targeted biopsies of suspicious areas on MRI associated with random biopsies. RESULTS: After the second biopsy, the diagnosis of prostate adenocarcinoma was made in 64/150 cases. On a per-patient basis, MRSI had 82.8% sensitivity, 91.8% specificity, 88.3% positive predictive value (PPV), 87.8% negative predictive value (NPV) and 85.7% diagnostic accuracy. The sensitivity, specificity, PPV, NPV and accuracy for DCE-MRI was 76.5%, 89.5%, 84.5%, 83.7% and 82%, respectively. The combination of MRSI and DCE-MRI yielded 93.7% sensitivity, 90.7% specificity, 88.2% PPV, 95.1% NPV and 90.9% accuracy in detecting prostate carcinoma. CONCLUSIONS: The combined study with [¹H]MRSI and DCE-MRI showed promising results in guiding the biopsy of cancer foci in patients with an initial negative TRUS-guided biopsy.
Authors: A E Wefer; H Hricak; D B Vigneron; F V Coakley; Y Lu; J Wefer; U Mueller-Lisse; P R Carroll; J Kurhanewicz Journal: J Urol Date: 2000-08 Impact factor: 7.450
Authors: J C Vilanova; J Comet; A Capdevila; J Barceló; J L Dolz; M Huguet; C Barceló; J Aldomà; E Delgado Journal: Eur Radiol Date: 2001 Impact factor: 5.315
Authors: Axel Wetter; Frank Hübner; Thomas Lehnert; Klaus Fliessbach; Marianne Vorbuchner; Stefan Roell; Stephan Zangos; Wolfgang Luboldt; Thomas J Vogl Journal: Eur Radiol Date: 2004-12-31 Impact factor: 5.315
Authors: Rajeev Kumar; Rishi Nayyar; Virendra Kumar; Narmada P Gupta; Ashok K Hemal; N R Jagannathan; S Dattagupta; S Thulkar Journal: Urology Date: 2008-03-10 Impact factor: 2.649
Authors: Armando Stabile; Francesco Giganti; Andrew B Rosenkrantz; Samir S Taneja; Geert Villeirs; Inderbir S Gill; Clare Allen; Mark Emberton; Caroline M Moore; Veeru Kasivisvanathan Journal: Nat Rev Urol Date: 2019-07-17 Impact factor: 14.432
Authors: Mai Lin Nguyen; Brooke Willows; Rihan Khan; Alexander Chi; Lyndon Kim; Sherif G Nour; Thomas Sroka; Christine Kerr; Juan Godinez; Melissa Mills; Ulf Karlsson; Gabor Altdorfer; Nam Phong Nguyen; Gordon Jendrasiak Journal: Front Oncol Date: 2014-05-05 Impact factor: 6.244